In this prospective study, the efficacy and safety of conventional therapy, pegylated interferon alpha-2a, and ruxolitinib in the treatment of MPNs were compared.
Study results presented at the annual meeting of the American Society of Hematology suggest that the estimated 4-year mortality rate among patients with polycythemia vera is more than 10%, and that causes of death vary.
The efficacy and safety of direct oral anticoagulants and vitamin K antagonists in the treatment of ATEs/VTEs in patients with MPNs was compared.
An analysis of data from the NIH-AARP Diet and Health Study evaluated the association between consumption of various foods and the development of MPN.
Patients with myelofibrosis conditioned with 2 alkylating agents may have better transplant outcomes compared with patients receiving 1 alkylating agent.